Evaluation of Dry Eyes
Defines plan reimbursement criteria for laboratory tests used in evaluation and monitoring of dry eye disease for BCBSIL products; notes not all requirements apply to every product and plan documents govern coverage specifics.
New policy effective 01/01/2026 (Approval date 09/05/2025).
Policy summary
Background: BCBSIL implemented lab management reimbursement criteria for evaluation of dry eye. This policy clarifies which tear-based tests are considered reimbursable versus not reimbursable for individuals suspected of having dry eye disease and provides examples of related procedure codes (e.g., 82785, 83516, 83520, 83861).
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.